Dr. Reddy's Laboratories Limited (DRREDDY) Q2 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

Dr. Reddy's Laboratories is a pharmaceutical company developing and marketing generics, branded generics, biosimilars and innovative therapies, and its Q2 print comes with the semaglutide supply pause and the lenalidomide revenue transition still weighing on the numbers. The two most material things the results will speak to are whether the semaglutide restart stays on track against the November target and how far reported margins can close the gap to the ~20% ex-semaglutide guidance from Q1's 12.5%.

Dr. Reddy's Laboratories Limited Q2 Results Date and Time

Per the company's intimation, Q2FY27 (quarter and six months ended Sep 30, 2026) results are to be released Friday, Oct 23, 2026 after the Board meeting. The Board meeting on Oct 23, 2026 is scheduled to approve Q2FY27 unaudited standalone and consolidated results.

The company has scheduled its earnings call for Oct 23, 2026 at 19:30 IST / 10:00 AM ET, following the results release after the Board meeting.

What to expect from Dr. Reddy's Laboratories Limited's Q2 FY27 results

The quarter just closed sits entirely inside the semaglutide supply pause, so the GLP-1 franchise contributes no revenue in Q2, and the CFO's Sep 28 framing — reintroduction by December, with new API batches from OneSource starting production by December — points to meaningful pen volumes landing in H2. North America, the largest geography with FY26 revenue of Rs. 113,737 Mn (US$1,212 Mn), enters Q2 off a -41% YoY Q1 (US$236 Mn) driven by the lenalidomide transition, with the company's own presentation flagging US generics price erosion as moderate and double-digit base-business growth ex-lenalidomide (DRL 10.3% vs US generics market 2.1%). India grew 16.8% YoY in Q1, within the 15-16% guided range, while Europe at €131 Mn was broadly flat YoY, making these the offsetting legs to the North America decline. On margins, Q1's reported EBITDA margin of 12.5% (15.4% excluding the Rs. 239.7 Cr semaglutide API provision) versus management's ~20% ex-semaglutide guide leaves a gap Q2 must close on operating lines, with SG&A up 12.4% YoY in Q1 against a flat nominal FY27 guide and R&D guided at 7-8% of revenues. On the Jul 22 call, management framed FY27 as H2-weighted with a strong second half on semaglutide resumption, though it conceded some disrupted value cannot be recovered; the upcoming call is expected to cover the semaglutide restart status, the North America trajectory and the margin bridge.

Key Things To Watch

Performance vs previously stated guidance: Management's stated anchors from the Q1FY27 call, and where each stands:

• EBITDA margin — ~20% ex-semaglutide — open-ended guidance (period not stated)
• Capex — ~Rs. 1,800 Cr — open-ended guidance
• R&D spend — 7-8% of revenues — open-ended guidance
• Tax rate — 24-25% — open-ended guidance
• Semaglutide commercial supplies resumption — by November; volumes of 6-7 million pens over Nov-Mar
• Abatacept BLA — US goal date mid-December 2026; QDENGA India private-market availability anticipated H1 2027

Semaglutide restart and root cause closure: The single biggest program overhang after the Rs. 239.7 Cr provision:

• Status of root cause analysis and resolution — a direct analyst follow-up from the Q1FY27 call whose answer was not in the retrieved excerpt
• Whether commercial supplies resumed by the November target, and credibility of the 6-7 million pen Nov-Mar ramp given the CFO's Sep 28 timeline of reintroduction by December with OneSource batch production from December
• Any fresh provision or reversal of the Rs. 239.7 Cr provision for out-of-specification semaglutide API batches

North America generics trajectory: The largest geography enters Q2 off a steep decline:

• Whether the -41% YoY Q1 decline (US$236 Mn) moderates, and capture of the bosutinib 180-day exclusivity window in a ~$300 Mn market
• Reconciling the 'healthy double-digit growth' base-business characterization with reported consolidated revenue of Rs. 8,070.5 Cr, down 5.6% YoY
• Whether the QoQ improvement pattern (revenue +7.4% QoQ, EBITDA +2.87% QoQ, PAT +101.50% QoQ in Q1FY27) extends into Q2FY27

USFDA inspections and regulatory follow-through: Inspection intensity has been high across the window:

• Follow-through on five window Form 483s (2-4 observations each), including the June 2026 Bachupally biologics PLI with 7 observations (responses submitted) and the Oct 8-9 PAI at FTO-9, Visakhapatnam with 3 observations
• Abatacept BLA progress toward the mid-December 2026 goal date and QDENGA launch preparation ahead of anticipated H1 2027 availability